: Currently the market's top performer in 2026, with a YTD return of 393.9% as of March following the successful commercial launch of its cancer therapy, Anktiva.
The following stocks have shown significant year-to-date (YTD) returns or recent technical breakouts: momentum stocks to buy now
: A clinical-stage biotech focused on cancer treatments, gaining 267.2% YTD due to positive Phase 1 clinical data. : Currently the market's top performer in 2026,
Short-term traders are currently monitoring stocks with Relative Strength Index (RSI) levels indicating active buying interest: momentum stocks to buy now